Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 29/03/18 at 10:51am

As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if you're lucky enough to benefit from one. That also means that this week's Top Ten comes a little earlier than usual.

As always there was a wide range of big stories this week, including the news that GSK had written itself out of the picture in the race to acquire Pfizer's Consumer Health Unit, and the discovery of a new organ in the human body which coulld change the way we view cancer treatment. But the most popular story of the week was the news that Roche's blockbuster haemophilia treatment Hemlibra has been linked to the deaths of five patients since the end of last year.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Roche’s Tecentriq improves OS in first-line lung cancer

Roche has revealed further data from a Phase 3 trial, which showed that a combination of Tecentriq and Avastin, in addition to carboplatin and paclitaxel, was able to improve overall survival in the treatment of advanced non-squamous non-small cell lung cancer.

9. Sun Pharma receives approval for first biologic drug

The beginning of Sun Pharma’s diversification out of generic drugs is here and it’s a drug that MSD was happy to pass over to the Indian pharma company.

8. Ablynx's vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus

Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint in a Phase 2 trial  which also saw the deaths of two patients.

7. Promising drug for hormone therapy-resistant breast cancer enters human trials

A team of researchers at Chicago’s University of Illinois (UIC) have revealed that their promising drug which could prove an effective treatment for breast cancer patients who have proved unresponsive to hormone therapy has entered human trials.

6. Lifestyle factors to blame for 38% of cancers

A new study by Cancer Research UK has found that more than 135,500 cases of cancer every year in the UK are due to lifestyle habits, meaning that 37.7% of cancers could potentially be prevented by making simple changes.

5. Six reasons why UK pharma has more to gain, than fear, from Brexit

There are good reasons to think exiting the EU represents a major opportunity for this dynamic and world-leading industry, argues Tom Cowap of Catalyst Corporate Finance.

4. Takeda and TiGenix's Alofisel becomes first donor-derived stem cell therapy approved in Europe

The European Commission has awarded approval to Takeda and TiGenix’s allogeneic expanded adipose-derived stem cell therapy Alofisel for the treatment of complex perianal fistulae in adult patients with nonactive/mildly active luminal Crohn’s disease, when fistulae have shown an inadequate response to at least one conventional or biologic therapy, it has emerged.

3. New organ discovery has implications for cancer treatment

The discovery of an entirely new organ, the 80th to be discovered in the human body, could have serious implications for our collective understanding of cancer and a number of other diseases.

2. GSK withdraws from running for Pfizer Consumer Health

GSK has announced that it has decided to pull out of the race to acquire Pfizer’s Consumer Health business, ending months of speculation.

1. Five deaths linked to Roche's haemophilia drug Hemlibra

Roche has been rocked by the revelation that there have been five patient deaths linked to the use of its bispecific factor IXa- and factor X-directed antibody Hemlibra, sending its shares slipping.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches